Understanding how T-LGL leukemia resists treatment and finding new therapies
Official title: Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia
Funded at Ohio State University · NIH-11004692 · Data updated 2026-11-12
This study is looking at a rare type of blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL) to understand why some treatments don't work well and to find new options, especially ones that target a substance called interleukin-15, which plays a big role in the disease, so that patients can have better outcomes and rely less on treatments that weaken their immune system.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $78,750 |
| NIH project number | 5R03CA286694-02 |
| Project ID | NIH-11004692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL) who are experiencing severe symptoms such as anemia and recurrent infections.
✕Less likely to help
Patients with other types of leukemia or those who do not have T-LGLL may not benefit from this research.
What this research studies
This research focuses on T-cell large granular lymphocytic leukemia (T-LGLL), a rare and challenging blood cancer that leads to severe anemia and recurrent infections. The study aims to investigate the underlying mechanisms of resistance to current therapies and explore new targeted treatments, particularly those that inhibit interleukin-15 (IL-15), a key driver of the disease. By analyzing patient responses to a specific peptide therapy, the research seeks to identify effective strategies to improve patient outcomes and reduce reliance on less effective immune-suppressive treatments.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective therapies for T-LGLL, significantly improving patient quality of life and survival rates.
How similar studies have gone: Previous research has shown some success in targeting IL-15 in similar conditions, indicating potential for this approach in T-LGLL.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Brammer, Jonathan Edward — Ohio State University
- Study coordinator: Brammer, Jonathan Edward
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.